期刊
EUROPEAN STROKE JOURNAL
卷 7, 期 1, 页码 15-19出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/23969873211072402
关键词
intracerebral hemorrhage; hemorrhage; cerebral hemorrhage; intraventricular hemorrhage; spot sign; CT scan; hematoma expansion
资金
- Australian National Health and Medical Research Council [1081718]
- Royal Melbourne Hospital Foundation
- National Health and Medical Research Council of Australia [1081718] Funding Source: NHMRC
This study evaluated the effect of tranexamic acid (TXA) on the growth of intraventricular hemorrhage (IVH) in acute intracerebral hemorrhage (ICH). The results showed that TXA may attenuate the development of IVH following ICH. However, larger studies are needed to further investigate this finding.
Background: Trials of tranexamic acid (TXA) in acute intracerebral hemorrhage (ICH) have focused on the imaging outcomes of intraparenchymal hematoma growth. However, intraventricular hemorrhage (IVH) growth is also strongly associated with outcome after ICH. Revised definitions of hematoma expansion incorporating IVH growth have been proposed. Aims: We sought to evaluate the effect of TXA on IVH growth. Methods: We analyzed data from the STOP-AUST trial, a prospective randomized trial comparing TXA to placebo in ICH patients presenting <= 4.5 h from symptom onset with a CT-angiography spot sign. New IVH development at follow-up, any interval IVH growth, and IVH growth >= 1 mL were compared between the treatment groups using logistic regression. The treatment effect of TXA against placebo using conventional (> 6 mL or 33%), and revised definitions of hematoma expansion (> 6 mL or 33% or IVH expansion >= 1 mL, > 6 mL or 33%, or any IVH expansion, and > 6 mL or 33% or new IVH development) were also assessed. Treatment effects were adjusted for baseline ICH volume. Results: The analysis population consisted of 99 patients (50 placebo, 49 TXA). New IVH development at follow-up was observed in 6/49 (12%) who received TXA and 13/50 (26%) who received placebo (aOR: 0.38 [95% CI: 0.13-1.13]). Any interval IVH growth was observed in 12/49 (25%) who received TXA versus 26/50 (32%) receiving placebo (aOR: 0.69 [95% CI: 0.28-1.66]). IVH growth >= 1 mL did not differ between the two groups. Using revised definitions of hematoma expansion, no significant difference in treatment effect was observed between TXA and placebo. Conclusions: IVH may be attenuated by TXA following ICH; however, studies with larger cohorts are required to investigate this further.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据